Shots:
- Lantheus will acquire Evergreen Theragnostics for $250M upfront plus ~$752.5M development & sales milestones related to Octevy & other assets in an all-cash transaction, with closing anticipated in H2’25 pending regulatory approvals
- The acquisition will add Evergreen’s Octevy (registrational-stage PET imaging agent for somatostatin receptor +ve NETs in adults & pediatrics) complementing Lantheus’ PNT2003, a drug discovery & early-stage clinical development tech as well as early-stage oncology & radiotherapeutic candidates
- Lantheus will also acquire Evergreen’s RLT manufacturing infrastructure, revenue-generating CDMO business as well as isotope expertise, enhancing development, production & long-term growth
Ref: Lantheus Holdings | Image: Evergreen Theragnostics
Related News:- Lantheus Strengthens its Alzheimer’s Disease Pipeline Through the Acquisition of Meilleur Technologies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
